Expert Answers to Questions on PARP Inhibition for Prostate Cancer

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:

• Germline and somatic mutation testing
• Managing adverse events with PARP inhibitors
• Resistance to PARP inhibitors
• Implications of monoallelic vs biallelic BRCA mutations
• ATM mutations and PARP inhibitor sensitivity

Presenters:

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/2P31ZqF